PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2190873
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2190873
The Structural Heart Devices Market reached USD 19 billion in 2025 and is projected to grow at 8.4% CAGR from 2026 to 2035. The market is expected to cross USD 43.02 billion valuation by 2035.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $19 Billion |
| Forecast Value | $43.02 Billion |
| CAGR | 8.4% |
CVDs caused 19.2 million deaths globally in 2023, with ischemic heart disease affecting 240 million people. Expanding prevalence of valve disease and structural cardiac abnormalities in an aging population enlarges the addressable patient pool for transcatheter and surgical structural heart procedures. Sustained burden development path supports above-average procedure volume growth through 2035, especially in regions with expanding elderly cohorts and improving diagnosis rates. Over 106,000 TAVR procedures were performed across U.S. centers in 2024. High and rising procedural volumes confirm robust structural heart program activity, supporting per-procedure device revenue and a growing base of existing installations with upgrade and revision potential. Continued procedural volume growth, broadening indications into moderate and low-risk patients, and expanding mitral and tricuspid platforms support forecast-period revenue growth. CT-based three-dimensional anatomical assessment, AI-allowed valve sizing simulation, and low-profile advanced delivery systems enabling complex structural anatomy access. Iterative platform advancement extends treatment eligibility to younger and anatomically challenging patients, adding new procedure categories and replacement demand on top of primary procedure growth. Successive-generation device launches and installed equipment revision cycles sustain dual revenue streams throughout the forecast period. Cardiovascular disease continues as the leading cause of death globally, accounting for 19.8 million deaths in 2022, or approximately 32% of all deaths worldwide. For structural heart suppliers, patient numbers alone do not determine procedures. Diagnosis, referral, and multidisciplinary assessment influence whether valve disease, septal defects, or atrial appendage risks receive intervention. Care networks that recognize suitable patients early and arrange specialist assessment can convert clinical need into treatment. Experience with TAVR provides a practical foundation for extending transcatheter procedures. As heart teams gain procedural confidence, hospitals can extend well-developed imaging, anesthesia, catheterization, and follow-up infrastructure into mitral, tricuspid, and closure therapies. Product innovation strengthens that transition by improving navigability, sizing precision, sealing performance, and access in challenging anatomy. The resulting opportunity is both procedural and replacement-driven: newer platforms can treat additional patients while creating revision demand within an expanding base of existing installations.
Based on product, the Transcatheter heart valves segment generated USD 8.17 billion in 2025. The well-developed role of transcatheter aortic valve replacement and the gradual broadening of transcatheter treatment across mitral, tricuspid, and pulmonary valve disease helps explain their commercial standing. Device selection progressively turns on anatomy-specific sizing, delivery profile, repositionability, durability expectations, and compatibility with valve-in-valve treatment, making platform breadth a central competitive consideration.
Within procedure, the TAVR segment generated USD 8.93 billion in 2025. The procedure continues as the commercial anchor of the market as it has well-developed referral patterns, standardized heart-team workflows, and broad clinical familiarity across risk categories. Its future mix will be influenced by treatment of younger patients, valve-in-valve cases, lifetime management considerations, and the ability of producers to differentiate on hemodynamics, access, and coronary reaccess.
The North America structural heart devices market generated USD 9.12 billion in 2025. The region gains from well-developed structural heart referral networks, advanced imaging capacity, and broad clinical experience with transcatheter valve and closure procedures. Its relative global weight is likely to moderate as emerging regions scale more rapidly, but its base of existing installations, reimbursement infrastructure, and early adoption of successive device generations preserve its role as the well-developed commercial market.
Edwards Lifesciences held over 31.1% of the market in 2025.
Some of the major players in this market are Medtronic, Abbott, Boston Scientific, AtriCure. This structural heart devices market is concentrated, with key players including Edwards Lifesciences, Medtronic plc, Abbott, Boston Scientific Corporation, LivaNova PLC, AtriCure, Artivion (formerly CryoLife), BIOMERICS, BRAILE Biomedica, JenaValve Technology, Lepu Medical Technology, and NuMED Inc. Market leadership develops in response to clinical evidence, regulatory expertise, physician training capabilities, specialist commercial infrastructure, and the ability to support complex structural heart procedures across valve replacement, valve repair, closure, and appendage management applications.